 |
 |
 |
|
 |
The U.S healthcare system is under tremendous stress as a result of unsustainable cost pressures, demographic shifts and the advent of new medical technologies. By personalizing medicine through better understanding of the individual we can improve patient care and greatly increase healthcare productivity. MDV funds entrepreneurs and cross-disciplinary teams focused on biomedical breakthroughs, molecular diagnostics and technology platforms that will deliver on this vision. |
|||||||||||||||||||||||||||
 |
Pacific Biosciences (PacBio) is developing a transformative single-molecule, real-time (SMRT) DNA sequencing platform. PacBio's goal is to commercialize SMRT DNA sequencing technology, eventually enabling sequencing of individual genomes as part of routine medical care. Founded in 2004.
Navigenics, Inc. specializes in personalized consumer health and wellness services, with the overall goal of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact.
Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers - biomarkers - that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. Founded in 2002
CardioDx is a molecular diagnostics company developing clinically validated molecular diagnostics specifically for heart disease. These tests will help cardiologists identify patients who will benefit most from advanced cardiovascular therapies and predict risk for developing disease. Founded in 2004.
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its novel, proprietary technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
RainDance Technologies designed the Personal Laboratory System to be the chemical equivalent of a personal computer. The key to this innovation is the first combination of microdroplets and microfluidic systems to create digital packets of chemical information called NanoReactors. Like a computer manipulates bits of information, the PLS enables the programmable handling of cells and fluid samples for innovative assay and screening applications. Founded in 2004. www.raindancetechnologies.com/
> See more portfolio companies.
|
|
|
||||||||||||||||||||||||
      
|
|||||||||||||||||||||||||||
